Journal Club VL

18F-DCFPyL PET/CT Detection Rates in Patients with Biochemical Recurrent Prostate Cancer, Journal Club - Christopher Wallis & Zachary Klaassen

Details
In this UroToday Journal Club video presentation Drs Christopher Wallis and Zachary Klaassen highlight a Journal of Nuclear Medicine publication titled Predictors of 18F-DCFPyL PET/CT Positivity in Patients with Biochemical Recurrence of Prostate Cancer After Local Therapy which investigated the factors predicting scan positivity and disease location in patients with biochemical recurrence of pros...

The Benefit of Adding Short-Term ADT to Prostate Bed Salvage Radiotherapy to Prevent Prostate Cancer Progression, The SPPORT Trial, Journal Club - Christopher Wallis & Zachary Klaassen

Details
In this UroToday Journal Club video presentation Drs Christopher Wallis and Zachary Klaassen highlight a Lancet publication titled The Addition of Androgen Deprivation Therapy and Pelvic Lymph Node Treatment to Prostate Bed Salvage Radiotherapy, the NRG RTOG 0534 SPPORT trial, an international, multicenter, randomized Phase III trial which was designed to determine whether incremental gains in pat...

An Association Between Lower Facility Level PSA Screening Rates and Higher Metastatic Prostate Cancer Incidence Rates, Journal Club - Christopher Wallis & Zachary Klaassen

Details
In this UroToday Journal Club presentation, Christopher Wallis and Zachary Klaassen highlight a JAMA Oncology publication led by Alex Bryant and Brent Rose titled The Association of PSA Screening Rates with Subsequent Metastatic Prostate Cancer Incidents at US Veterans Health Administration Facilities. PSA Screening is relatively controversial. Adopted in the United States in the 1990s it was asso...

225Ac-PSMA-617 Post ADT in mCRPC Patients: Response to Treatment and Survival Analysis, Journal Club - Christopher Wallis & Zachary Klaassen

Details
Christopher Wallis and Zachary Klaassen discuss the Journal of Nuclear Medicine publication entitled "mCRPC Patients Receiving 225Ac-PSMA-617 Therapy in Post Androgen Deprivation Therapy Setting: Response to Treatment and Survival Analysis." In low and middle-income countries, the treatment of prostate cancer is challenging due to a relatively advanced presentation of disease due to a lack of regu...

Long-Term Follow-Up Results (CheckMate 9ER) Trial, Journal Club - Christopher Wallis & Zachary Klaassen

Details
In this UroToday Journal Club video presentation Christopher Wallis and Zachary Klaassen highlight the extended follow-up of overall survival and updated efficacy and safety in the CheckMate 9ER trial. The primary analysis of CheckMate 9ER showed nivolumab plus cabozantinib had superior progression-free survival, overall survival, and objective response over sunitinib in patients with previously u...

EV-201 Enfortumab Vedotin After PD-1 or PD-L1 Inhibitors in Cisplatin-Ineligible Patients with Advanced Urothelial Carcinoma, Journal Club - Christopher Wallis & Zachary Klaassen

Details
Christopher Wallis and Zach Klaassen delve into the EV-201 study. This phase 2 trial investigates the efficacy of enfortumab vedotin in treating cisplatin-ineligible patients with advanced urothelial carcinoma who have previously received PD-1 or PD-L1 inhibitors. The study, conducted across 59 sites in North America, Europe, and Asia, shows a promising objective response rate of 52%, with 20% of...

PSMA PET/CT Patterns to Optimize Prostate Cancer Diagnosis, The PRIMARY Score - Journal Club - Christopher Wallis & Zachary Klaassen

Details
In this UroToday Journal Club, Christopher Wallis and Zachary Klaassen highlight the Journal of Nuclear Medicine publication titled The PRIMARY Score: Using intra-prostatic PSMA PET/CT patterns to optimise prostate cancer diagnosis. In this posthoc analysis the PRIMARY study evaluated the clinical significance of patterns of intra-prostatic PSMA activity, proposing a 5- point PRIMARY score to opti...

Trends in Incidence of Metastatic Prostate Cancer in the US - Christopher Wallis & Zachary Klaassen

Details
Christopher Wallis and Zachary Klaassen discuss the publication entitled "Trends in Incidence of Metastatic Prostate Cancer in the US." Analysis of the emerging trends suggests that the incidence rates of metastatic prostate cancer have increased significantly and coincide temporally with the US Preventive Services Task Force (USPSTF) recommendations against prostate cancer screening across races...

Optimal Treatment for Poor Prognosis Metastatic Castration-Resistant Prostate Cancer, Cabazitaxel vs Abi/Enza, Journal Club – Christopher Wallis & Zachary Klaassen

Details
Christopher Wallis and Zachary Klaassen discuss the Annals of Oncology article titled “Cabazitaxel versus abiraterone or enzalutamide in poor prognosis metastatic castration-resistant prostate cancer: a multicentre, randomised, open-label, phase 2 trial.” The goal of this publication was to determine the optimal treatment for poor prognosis metastatic castration-resistant prostate cancer (mCRPC) p...

Safety and Activity of Alpha-Emitting Ac-225-PSMA-617 Radioligand Therapy in mCRPC That Has Progressed After Lu-177-PSMA, Journal Club – Christopher Wallis & Zachary Klaassen

Details
Christopher Wallis and Zachary Klaassen discuss a publication on the activity and adverse effects of Actinium-225 therapy, in advanced metastatic castrate resistant prostate cancer (mCRPC) patients, after the failure of their Lutetium-177 treatment. Dr. Wallis begins by discussing the topic of theranostics, and the difference between the beta-emitter, 177-Lutetium, and the alpha-emitter, 225-Actin...